Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Frankfurt - Delayed Quote • EUR Repligen Corporation (RGN.F) Follow Compare 110.00 -1.15 (-1.03%) As of 8:09:48 AM GMT+2. Market Open. Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for RGN.F 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: RGN.F View More All News Press Releases SEC Filings Repligen to Report First Quarter 2025 Financial Results Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings? Repligen Appoints Jacob Johnson As Vice President Investor Relations Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last? Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks Is Repligen Corporation (RGEN) the Top Stock to Buy According to 12 West Capital Management? Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock? Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack